Lecanemab is a breakthrough monoclonal antibody that targets and removes an abnormal form of amyloid, a protein that builds in the brains of people with Alzheimer’s. This approach doesn’t stop the disease process and does not improve cognitive symptoms or functional abilities. The benefit is likely different from person to person and at different stages of the disease.